The acquisition brings to Biota AP611074, a patented, direct-acting antiviral in clinical development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis (RRP), both of which are caused by human papillomavirus (HPV) types 6 and 11.
"We are excited to advance the clinical development of AP611074 and plan to initiate a Phase 2 trial in late 2015 to further validate its favorable local skin tolerability profile and antiviral activity," commented Joseph M. Patti, PhD., president and chief executive officer of Biota.
"AP611074 is uniquely positioned to significantly improve the treatment paradigm for anogenital warts, the most frequently sexually-transmitted viral disease worldwide, and RRP, a rare condition in which epithelial tumor-like lesions grow on the larynx."
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally.
The Company has four product candidates in development that address viral infections that have limited therapeutic options.
Vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; AP611074, a novel topical treatment for genital warts caused by HPV types 6 & 11; BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. For additional information about the Company, please visit www.biotapharma.com.